9.55
+0.10%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Syndax Pharmaceuticals
From its filings with the US Securities and Exchange Commission
Syndax Pharmaceuticals is based in New York, New York and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker SNDX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $172.4m and a net loss of $285.4m. At that date it held total assets of $529.7m and shareholders' equity of $64.6m. By business, Net Product Revenues [Member] brought in 72.4% of revenue, followed by Collaboration revenue [Member] at 24.6% and Milestone Revenue [Member] at 3.0%.
We are a commercial-stage biopharmaceutical company advancing innovative cancer therapies. We currently have two commercially approved medicines, Revuforj® (revumenib) and Niktimvo (axatilimab-csfr), and a robust slate of clinical development programs designed to unlock the full potential of our first two products.
Revuforj is our first-in-class menin inhibitor that was approved by the U.S. Food and Drug Administration, or FDA, in November 2024 for the treatment of relapsed or refractory, or R/R, acute leukemia with a lysine methyltransferase 2A gene, or KMT2A, translocation in adult and pediatric patients one year old and older. In October 2025, Revuforj received a second approval from the FDA for the treatment of R/R acute myeloid leukemia, or AML, with a susceptible nucleophosmin 1 mutation, or NPM1m, in adult and pediatric patients one year and older who have no satisfactory alternative treatment options. We are also studying revumenib in combination with standard-of-care agents in NPM1m AML and KMT2A-rearranged, or KMT2Ar, acute leukemia across the treatment landscape, including in newly diagnosed patients. Additionally, we are exploring the potential for menin inhibition in the treatment of myelofibrosis, or MF.
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 3 Mar 2016
- Employees
- 298
- Website
- syndax.com ↗
- Head office
- 730 THIRD AVENUE, NEW YORK, NY, 10017
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Dennis PodlesakIndependent Chairman of the Board$954,418
- Mr. Michael MetzgerChief Executive Officer, Director, since 2015$7.7m
- Mr. Keith GoldanChief Financial Officer$2.8m
- Mr. Luke AlbrechtGeneral Counsel, Secretary$2.5m
- Mr. Nicholas BotwoodHead - Research and Development, Chief Medical Officer
- Mr. Steven ClosterChief Commercial Officer$3.6m
- Dr. Martin HuberIndependent Director$441,519
- Ms. Jennifer JarrettIndependent Director$438,668
- Mr. Keith KatkinIndependent Director$507,193
- Mr. Pierre LegaultIndependent Director$501,490
- Dr. Aleksandra RizoIndependent Director$534,262
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 74
- Environment
- 82
- Social
- 99
- Governance
- 40
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Syndax Pharmaceuticals Inc has several key strengths that contribute to its success in the pharmaceutical industry.
Weaknesses
- Despite its strengths, Syndax Pharmaceuticals Inc also faces certain weaknesses that need to be addressed.
Opportunities
- Syndax Pharmaceuticals Inc can explore various opportunities in the marketplace to achieve growth and success.
Threats
- Syndax Pharmaceuticals Inc faces certain threats that could impact its business operations and growth.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.